Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator\'s choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study.
Epistemonikos ID: 112e773cfa7d28b2b5a2f7561bdfe8f4be62ecb2
First added on: May 10, 2024